Published in Drug Resist Updat on September 14, 2011
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma | NCT00872404
Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS One (2012) 0.97
Epidermal growth factor (EGF) regulates α5β1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A. J Biol Chem (2012) 0.93
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. Eur Arch Otorhinolaryngol (2013) 0.91
Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer (2012) 0.90
Autophagic action of new targeting agents in head and neck oncology. Cancer Biol Ther (2012) 0.85
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med (2015) 0.77
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization. BMC Cancer (2015) 0.76
Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. Otolaryngol Head Neck Surg (2016) 0.76
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther (2016) 0.75
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel) (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Network medicine: a network-based approach to human disease. Nat Rev Genet (2011) 14.07
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A (2005) 5.37
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem (1980) 5.19
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res (2002) 4.97
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 4.95
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell (2008) 4.22
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol (2005) 4.16
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A (2008) 3.87
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res (2009) 3.70
TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell (2010) 3.69
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily. Nature (1991) 3.31
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res (1995) 3.20
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature (2010) 3.12
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res (2000) 2.96
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res (2001) 2.90
Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer (2008) 2.85
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res (2005) 2.76
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res (1999) 2.71
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res (2005) 2.65
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 2.62
The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle (2009) 2.62
Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene (2009) 2.58
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol (2011) 2.47
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol (2010) 2.41
Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res (2002) 2.41
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther (2009) 2.37
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res (2007) 2.31
Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol (2005) 2.20
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One (2009) 2.18
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res (1984) 2.17
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol (2008) 2.10
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol (1993) 2.07
STAT-mediated EGFR signaling in cancer. J Cell Biochem (2007) 2.05
A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res (2006) 2.01
PISCES: a protein sequence culling server. Bioinformatics (2003) 11.87
A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci (2003) 9.25
HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell (2007) 6.50
Improved prediction of protein side-chain conformations with SCWRL4. Proteins (2009) 5.67
Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 4.83
Cyclic coordinate descent: A robotics algorithm for protein loop closure. Protein Sci (2003) 4.82
PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta (2010) 3.62
PISCES: recent improvements to a PDB sequence culling server. Nucleic Acids Res (2005) 3.55
A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. Structure (2011) 2.61
CAFASP3: the third critical assessment of fully automated structure prediction methods. Proteins (2003) 2.60
The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol (2005) 2.52
Conformation dependence of backbone geometry in proteins. Structure (2009) 2.33
Outcome of a workshop on archiving structural models of biological macromolecules. Structure (2006) 2.32
KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet (2002) 2.28
Outcome of a workshop on applications of protein models in biomedical research. Structure (2009) 2.05
Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol (2010) 1.93
Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. Proc Natl Acad Sci U S A (2010) 1.87
Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci (2012) 1.84
CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci (2009) 1.84
A new clustering of antibody CDR loop conformations. J Mol Biol (2010) 1.83
Assignment of protein sequences to existing domain and family classification systems: Pfam and the PDB. Bioinformatics (2012) 1.82
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) (2005) 1.80
SCWRL and MolIDE: computer programs for side-chain conformation prediction and homology modeling. Nat Protoc (2008) 1.79
Scoring profile-to-profile sequence alignments. Protein Sci (2004) 1.71
Assessment of disorder predictions in CASP6. Proteins (2005) 1.69
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res (2002) 1.66
Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64
Statistical analysis of interface similarity in crystals of homologous proteins. J Mol Biol (2008) 1.55
Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem (2008) 1.55
Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol (2004) 1.54
Cell cycle-dependent ciliogenesis and cancer. Cancer Res (2008) 1.54
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Increased recurrences using intensity-modulated radiation therapy in the postoperative setting. Am J Clin Oncol (2010) 1.52
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A (2002) 1.52
A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res (2007) 1.48
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Neighbor-dependent Ramachandran probability distributions of amino acids developed from a hierarchical Dirichlet process model. PLoS Comput Biol (2010) 1.44
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol (2013) 1.42
Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A (2004) 1.42
Assessment of fold recognition predictions in CASP6. Proteins (2005) 1.41
MollDE: a homology modeling framework you can click with. Bioinformatics (2005) 1.40
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2014) 1.39
Statistical and conformational analysis of the electron density of protein side chains. Proteins (2007) 1.35
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
The protein common interface database (ProtCID)--a comprehensive database of interactions of homologous proteins in multiple crystal forms. Nucleic Acids Res (2010) 1.30
Dissection of HEF1-dependent functions in motility and transcriptional regulation. J Cell Sci (2002) 1.29
Primary cilia and the cell cycle. Methods Cell Biol (2009) 1.28
HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle (2006) 1.25
Nonplanar peptide bonds in proteins are common and conserved but not biased toward active sites. Proc Natl Acad Sci U S A (2011) 1.23
Alternative splicing affecting a novel domain in the C. elegans EGL-15 FGF receptor confers functional specificity. Development (2003) 1.20
Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle. Mol Biol Cell (2006) 1.19
BioDownloader: bioinformatics downloads and updates in a few clicks. Bioinformatics (2007) 1.14
A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res (2013) 1.14
Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. Mol Biol Cell (2012) 1.13
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J (2003) 1.12
A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. Arch Biochem Biophys (2013) 1.11
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res (2003) 1.10
Aurora A kinase activity influences calcium signaling in kidney cells. J Cell Biol (2011) 1.10
ProtBuD: a database of biological unit structures of protein families and superfamilies. Bioinformatics (2006) 1.09
The role of balanced training and testing data sets for binary classifiers in bioinformatics. PLoS One (2013) 1.09
Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev (2008) 1.09
Interdependence of cell attachment and cell cycle signaling. Curr Opin Cell Biol (2006) 1.08
A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell (2008) 1.07
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2003) 1.07
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
The GDP exchange factor AND-34 is expressed in B cells, associates with HEF1, and activates Cdc42. J Immunol (2003) 1.06
NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One (2011) 1.06
Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.06
A novel RING finger protein, human enhancer of invasion 10, alters mitotic progression through regulation of cyclin B levels. Mol Cell Biol (2003) 1.06
Domain definition and target classification for CASP6. Proteins (2005) 1.06
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm (2005) 1.06
A forward-looking suggestion for resolving the stereochemical restraints debate: ideal geometry functions. Acta Crystallogr D Biol Crystallogr (2008) 1.05
UNC-71, a disintegrin and metalloprotease (ADAM) protein, regulates motor axon guidance and sex myoblast migration in C. elegans. Development (2003) 1.04
The extracellular matrix and ciliary signaling. Curr Opin Cell Biol (2012) 1.03
Minimal ensembles of side chain conformers for modeling protein-protein interactions. Proteins (2011) 1.03
Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase. Proteins (2010) 1.03
Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res (2010) 1.02
Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol (2003) 1.02
Assignment of protonation states in proteins and ligands: combining pKa prediction with hydrogen bonding network optimization. Methods Mol Biol (2012) 1.02
Bimodal population or pathologist artifact? J Clin Oncol (2007) 1.00
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proc Natl Acad Sci U S A (2012) 0.99
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. Cancer Res (2003) 0.99
Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol (2011) 0.99
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics (2009) 0.98
Rapid calcium-dependent activation of Aurora-A kinase. Nat Commun (2010) 0.98
Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets (2009) 0.96
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res (2010) 0.96
Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res (2002) 0.96
Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med (2004) 0.93